These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Ready N Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534 [TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402 [TBL] [Abstract][Full Text] [Related]
5. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145 [TBL] [Abstract][Full Text] [Related]
6. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Herbst RS Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982 [TBL] [Abstract][Full Text] [Related]
7. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Sanford M; Scott LJ Drugs; 2009 Nov; 69(16):2303-28. PubMed ID: 19852530 [TBL] [Abstract][Full Text] [Related]
10. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK; J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950 [TBL] [Abstract][Full Text] [Related]
12. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
13. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Adis International Ltd Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590 [TBL] [Abstract][Full Text] [Related]
14. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256 [TBL] [Abstract][Full Text] [Related]
15. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Burotto M; Manasanch EE; Wilkerson J; Fojo T Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635 [TBL] [Abstract][Full Text] [Related]
16. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663 [TBL] [Abstract][Full Text] [Related]
17. [Molecular targeted therapy--non-small-cell lung cancer and gefitinib]. Shimizu J; Horio Y; Mitsudomi T Gan To Kagaku Ryoho; 2005 Nov; 32(12):1879-85. PubMed ID: 16282720 [TBL] [Abstract][Full Text] [Related]
18. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488 [TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). Tammaro KA; Baldwin PD; Lundberg AS J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601 [TBL] [Abstract][Full Text] [Related]
20. Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Natale RB Semin Oncol; 2004 Jun; 31(3 Suppl 9):23-30. PubMed ID: 15206079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]